The capsule drug ring (CDR) is a reservoir and delivery agent, which is designed to be placed within the capsular bag during cataract surgery. Prototypes were manufactured by hot melt extrusion of Bionate II ？, a polycarbonate urethane. The devices have been optimized using Avastin ？ as the drug of interest. In vitro biocompatibility was assessed with human lens epithelial cell (B-3), mouse macrophage (J774A.1) and mouse fibroblast (L-929) cell lines. Cell migration and proliferation were assessed after in vitro culture. Pro-inflammatory cytokines ( i.e., MIP-1β, MIP-1α, MCP-1, IL-1β, TNF and TGF-β1) were quantified using cytometric bead array (CBA). Preliminary in vivo biocompatibility and pharmacokinetics testing has been performed in rabbits.
References
[1]
Congdon, N.G.; Friedman, D.S.; Lietman, T. Important causes of visual impairment in the world today. J. Am. Med. 2003, 290, 2057–2060.
[2]
Ferrara, N.; Heinsohn, H.; Walder, C.E.; Bunting, S.; Thomas, G.R. The regulation of blood vessel growth by vascular endothelial growth factor. Ann. N.Y. Acad. Sci. 1995, 752, 246–256, doi:10.1111/j.1749-6632.1995.tb17435.x.
[3]
Kaufman, S.R. Developments in age-related macular degeneration: Diagnosis and treatment. Geriatrics 2009, 64, 16–19.
[4]
Nagy, J.A.; Dvorak, A.M.; Dvorak, H.F. VEGF-A and the induction of pathological angiogenesis. Annu. Rev. Pathol. 2007, 2, 251–275, doi:10.1146/annurev.pathol.2.010506.134925.
[5]
Qazi, Y.; Maddula, S.; Ambati, B.K. Mediators of ocular angiogenesis. J. Genet. 2009, 88, 495–515, doi:10.1007/s12041-009-0068-0.
[6]
Dvorak, H.F. Vascular permeability factor/vascular endothelial growth factor: A critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy. J. Clin. Oncol. 2002, 20, 4368–4380, doi:10.1200/JCO.2002.10.088.
[7]
Ellis, L.M.; Hicklin, D.J. VEGF-targeted therapy: Mechanisms of anti-tumour activity. Nat. Rev. Cancer 2008, 8, 579–591, doi:10.1038/nrc2403.
[8]
Ferrara, N.; Gerber, H.P.; LeCouter, J. The biology of VEGF and its receptors. Nat. Med. 2003, 9, 669–676, doi:10.1038/nm0603-669.
[9]
Bergers, G.; Hanahan, D. Modes of resistance to anti-angiogenic therapy. Nat. Rev. Cancer 2008, 8, 592–603, doi:10.1038/nrc2442.
[10]
Bourges, J.L.; Bloquel, C.; Thomas, A.; Froussart, F.; Bochot, A.; Azan, F.; Gurny, R.; BenEzra, D.; Behar-Cohen, F. Intraocular implants for extended drug delivery: Therapeutic applications. Adv. Drug Deliv. Rev. 2006, 58, 1182–1202, doi:10.1016/j.addr.2006.07.026.
[11]
Campbell, M.; Nguyen, A.T.; Kiang, A.S.; Tam, L.C.; Gobbo, O.L.; Kerskens, C.; Ni Dhubhghaill, S.; Humphries, M.M.; Farrar, G.J.; Kenna, P.F.; Humphries, P. An experimental platform for systemic drug delivery to the retina. Proc. Natl. Acad. Sci. USA 2009, 106, 17817–17822.
[12]
Daugherty, A.L.; Mrsny, R.J. Formulation and delivery issues for monoclonal antibody therapeutics. Adv. Drug. Deliv. Rev. 2006, 58, 686–706, doi:10.1016/j.addr.2006.03.011.
[13]
Gorle, A.P.; Gattani, S.G. Design and evaluation of polymeric ocular drug delivery system. Chem. Pharm. Bull. 2009, 57, 914–919, doi:10.1248/cpb.57.914.
[14]
Jaffe, G.J.; Yang, C.H.; Guo, H.; Denny, J.P.; Lima, C.; Ashton, P. Safety and pharmacokinetics of an intraocular fluocinolone acetonide sustained delivery device. Investig. Ophthalmol. Vis. Sci. 2000, 41, 3569–3575.
[15]
Kimura, H.; Ogura, Y. Biodegradable polymers for ocular drug delivery. Ophthalmologica 2001, 215, 143–155, doi:10.1159/000050849.
[16]
Lavik, E.; Kuehn, M.H.; Kwon, Y.H. Novel drug delivery systems for glaucoma. Eye 2011, 25, 578–586, doi:10.1038/eye.2011.82.
[17]
Li, P.-Y.; Shih, J.; Lo, R.; Saati, S.; Agrawal, R.; Humayun, M.S.; Tai, Y.-C.; Meng, E. An electrochemical intraocular drug delivery device. Sens. Actuators A Phys. 2008, 143, 41–48, doi:10.1016/j.sna.2007.06.034.
[18]
Saettone, M.F.; Salminen, L. Ocular inserts for topical delivery. Adv. Drug Deliv. Rev. 1995, 16, 95–106, doi:10.1016/0169-409X(95)00014-X.
